Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclosporine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA known ✓ | P62937 | 5/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 13/20 | 1.00 |
| ▸ | PPP3CA | Q08209 | 3/20 | 1.00 |
| ▸ | FKBP1B | P68106 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | TACR2 | P21452 | 1/20 | 1.00 |
| ▸ | PPIB | P23284 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclosporine SCHEMBL21170318 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23382247 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239446 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24224445 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL25083206 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239035 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL23192320 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23110210 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239036 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL23192319 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229077-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230383289-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230340466-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340465-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340467-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11696915-B2 | Methods and compositions for the treatment of hair loss | Aneira Pharma, Inc. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11643652-B2 | Methods and compositions for prime editing nucleotide sequences | THE BROAD INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11541053-B2 | Methods and compositions for the treatment of hair loss | Aneira Pharma, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11541054-B2 | Methods and compositions for the treatment of hair loss | Aneira Pharma, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11253518-B2 | Methods and compositions for the treatment of hair loss | Aneira Pharma, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-9919028-B2 | Autoclavable suspensions of cyclosporin A Form 2 | ALLERGAN, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-7902155-B2 | For treatment of mucin deficiency (dry mouth syndrome, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, oral mucosa cancer, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, ulcers, peptic ulcers, conditions affecting the uterus and appendicitis) | ALLERGAN, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100317595-A1 | COMPOSITIONS FOR ENHANCING NAIL GROWTH | ALLERGAN, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100144609-A1 | METHODS USING CYCLOSPORIN IN TREATING PATIENTS WITH INTRAOCULAR LENSES | DONNENFELD ERIC D | 2010-06-10 | — | — | US | disclosed |
| US-7655625-B2 | Methods of treating blepharospasm using cyclosporine components | ALLERGAN, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20090298753-A1 | METHODS FOR THE THERAPEUTIC USE OF CYCLOSPORINE COMPONENTS | ALLERGAN, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7368426-B2 | Methods for the therapeutic use of cyclosporine components | ALLERGAN, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080076707-A1 | Methods for the therapeutic use of cyclosporine components | ALLERGAN, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20070299004-A1 | Methods of providing therapeutic effects using cyclosporin compontnts | ALLERGAN, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070191266-A1 | METHODS OF TREATING BLEPHAROSPASM USING CYCLOSPORINE COMPONENTS | ALLERGAN, INC. | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541054-B2 | Methods and compositions for the treatment of hair loss | COXFA4L2, UNG, TYR | PPIA 713/4885ABCB1 4427/4885PPP3CA 159/4885 |
| US-20070299004-A1 | Methods of providing therapeutic effects using cyclosporin compontnts | IL2, CHP1, MALT1 | PPIA 613/4885ABCB1 384/4885PPP3CA 235/4885 |
| US-11253518-B2 | Methods and compositions for the treatment of hair loss | COXFA4L2, UNG, TYR | PPIA 713/4885ABCB1 4427/4885PPP3CA 159/4885 |
| US-20080076707-A1 | Methods for the therapeutic use of cyclosporine components | MALT1, FKBP5, FKBP1A | PPIA 44/4885ABCB1 3468/4885PPP3CA 78/4885 |
| US-11696915-B2 | Methods and compositions for the treatment of hair loss | COXFA4L2, UNG, TYR | PPIA 713/4885ABCB1 4427/4885PPP3CA 159/4885 |
| US-20230340465-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | RNGTT, POLRMT, POLM | PPIA 2916/4885ABCB1 3907/4885PPP3CA 1818/4885 |
| US-20100144609-A1 | METHODS USING CYCLOSPORIN IN TREATING PATIENTS WITH INTRAOCULAR LENSES | CRYAB, FKBP3, FKBP2 | PPIA 38/4885ABCB1 833/4885PPP3CA 269/4885 |
| US-20230340467-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | RNGTT, POLRMT, POLM | PPIA 2916/4885ABCB1 3907/4885PPP3CA 1818/4885 |
| US-20100317595-A1 | COMPOSITIONS FOR ENHANCING NAIL GROWTH | TYR, NACA, PIK3C3 | PPIA 2547/4885ABCB1 4495/4885PPP3CA 1095/4885 |
| US-11541053-B2 | Methods and compositions for the treatment of hair loss | COXFA4L2, UNG, TYR | PPIA 713/4885ABCB1 4427/4885PPP3CA 159/4885 |
| US-20070191266-A1 | METHODS OF TREATING BLEPHAROSPASM USING CYCLOSPORINE COMPONENTS | GABRR1, GABBR2, GABRR2 | PPIA 290/4885ABCB1 2247/4885PPP3CA 329/4885 |
| US-20090298753-A1 | METHODS FOR THE THERAPEUTIC USE OF CYCLOSPORINE COMPONENTS | MALT1, FKBP3, FKBP5 | PPIA 28/4885ABCB1 3407/4885PPP3CA 80/4885 |
| US-20230340466-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | POLRMT, RNGTT, POLM | PPIA 2986/4885ABCB1 3584/4885PPP3CA 2328/4885 |
| US-20230383289-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | RNGTT, POLRMT, POLM | PPIA 2916/4885ABCB1 3907/4885PPP3CA 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.